---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-24-000020"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:30:23.448844+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bionano Q1 revenue $8.8M (+18% YoY); cash burn down 41% YoY; restructuring charges $4.6M

## Summary
- Q1 2024 revenue $8.8M, +18% YoY; GAAP gross margin 32% vs 28% in Q1 2023.
- Operating cash burn (excl. interest/debt) $19M in Q1 2024, down from $32M in Q1 2023.
- Reaffirmed FY2024 revenue guidance of $37-41M; Q2 2024 revenue expected $7.8-8.2M.
- Installed base of 347 OGM systems (+34% YoY); flowcell sales up 58% to 8,249 units.
- Restructuring charges of ~$4.6M from March 2024 RIF; substantially complete by June 30, 2024.

## SEC filing metadata
- accession: 0001411690-24-000020
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/bngo-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-24-000020
- JSON: https://secwatch.observer/filing/0001411690-24-000020.json
- Plain text: https://secwatch.observer/filing/0001411690-24-000020.txt

## Key facts
- Earnings Releases
  Bionano Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $8.8 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $8.8 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress • Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 • Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023 •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm
- Restructurings & Charges
  Bionano Genomics, Inc. announced a restructuring with charges of approximately $4.6 million.
  - Type: restructuring
  - Charge: approximately $4.6 million
  source text: the Reduction is expected to result in total restructuring charges of approximately $4.6 million, including $3.9 million, comprised primarily of severance payments and wages for the 60-day notice period in accordance with the California Worker Adjustment and Retraining Notification (WARN) Act and $0.2 million in connection with lease terminations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169024000020/0001411690-24-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.